Open access
Nov 2026
Adverse event signals associated with targeted therapy plus chemotherapy in colorectal cancer: A FAERS-based pharmacovigilance study.
Real-world safety profiles of targeted therapies for colorectal cancer (CRC) remain incompletely characterized, particularly across different chemotherapy backbones. This study characterizes adverse event (AE) reporting patterns for bevacizumab (BVZ), cetuximab (C225), and panitumumab (VEC), used as monotherapy or in c...
You-Qiang Liu, Zhi-Han Li, Gang Li et al.
· Medicine · 0 citations